ANN ARBOR, Mich., Sept. 08, 2017 -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company will not renew the equity line with Calm Seas Capital, which expired in June of 2017.
The Company has maintained a financial relationship with Calm Seas Capital since before the creation of its first transgenic silkworm in 2010. After careful consideration of its plan for commercialization and expansion, and after reviewing potential alternatives for financing that expansion, the Company’s management has determined it has outgrown the financial relationship.
In addition to the recently extended U.S. Army contract, the Company implemented several strategic efficiency measures to reduce the Company’s fixed expenses.
“We value Calm Seas Capital’s contributions to many of our accomplishments, including the creation of new transgenics and recombinant fibers, however, given our projections for growth, this is the ideal time to transition for our business model’s next chapters,” said CEO and Founder, Kim Thompson. “As the Company has grown, and, in light of our plans for future expansion and the Army’s recent exercise of its contract option with us for spider silk, it is timely for the Company to explore other avenues that are better aligned with our long term goals. We’ve now grown to the point where we believe we have alternative financing options not previously available.”
To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC (720) 288-8495 [email protected]


Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Italy Fines Apple €98.6 Million Over App Store Dominance
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 



